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Measurement of left ventricular volumes and
function using O-15–labeled carbon monoxide
gated PET
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See related article, p. 639
Although single photon emission computed tomog-
raphy (SPECT) has been the cornerstone of noninvasive
assessment of coronary artery disease (CAD) and myo-
cardial perfusion imaging (MPI) for many years, MPI
now increasingly also involves positron emission tomog-
raphy (PET). In many centers equipped with PET facil-
ities, it provides a well-established technique that is
routinely used for the noninvasive imaging and quanti-
fication of myocardial perfusion and metabolism.
As PET has inherently implemented attenuation
correction, the accuracy of PET is expected to be
superior to that of SPECT. The recent introduction of
gated SPECT, however, has further increased the value
of SPECT MPI.1 In fact, end-diastolic and end-systolic
left ventricular (LV) volume and ejection fraction (EF)
are important predictors of prognosis and death in
patients with cardiac disease, particularly after myocar-
dial infarction but also in nonischemic cardiac disease.
Furthermore, parameters of regional and global LV
function are used to evaluate the efficacy of revascular-
ization in patients with CAD and chronic but reversible
LV dysfunction. Assessment of functional LV parame-
ters provides additional information, which substantially
increases the clinical impact of MPI. As no additional
radiation dose needs to be applied to get this information,
it should become the clinical standard to assess function
by use of electrocardiographic triggering. The old and
still valid rule that radiation dose should be kept as low
as reasonably achievable (ALARA) should now be
completed by the statement on clinical information—to
obtain as much as reasonably achievable (AMARA).
Similar to the development in gated SPECT, which has
brought a large number of validation studies for each
quantification method, this has now to be repeated by the
PET community. Consequently, different studies have
validated the measurement of LV volumes by electrocar-
diography-gated PET by use of different myocardial
tracers such as fluorine 18 fluorodeoxyglucose2-4 or
nitrogen 13 ammonia.5,6 For the blood pool tracer oxy-
gen 15–labeled carbon dioxide (CO), only limited data
from small pilot studies exist, in which the protocol was
specifically chosen to measure LV volumes by gating.7-9
In this issue of the Journal of Nuclear Cardiology,
Hofman et al10 provide evidence that LV volumes and
EF can be reliably measured noninvasively by means of
gated PET with the use of myocardial blood pool images
routinely acquired for use in perfusion quantification.
This contributes to the above-mentioned aim to obtain as
much information as reasonably achievable with any
application of any radiotracer. The authors did so with
2000 MBq O-15–labeled CO, resulting in an effective
dose equivalent of as low as around 0.3 mSv. This
certainly meets the criterion of ALARA, as it is lower by
about one order as compared with previous reports.7,9
Measurements were performed on a PET scanner and
compared with the gold standard, magnetic resonance
imaging.
Overall, despite a substantially shortened acquisition
time and lower dose, correlation was very good between
PET and magnetic resonance imaging for end-systolic (r
 0.90) and end-diastolic LV volumes (r  0.096) with
reasonable limits of agreement, although correlation was
slightly inferior for LV EF (r  0.86). Similar to
previous reports,7 LV EF tended to be underestimated.
The fact that EF was not measured on the same day by
the two different techniques is probably not the main
reason for these differences. It is much more plausible
that, inherently, two different techniques may not mea-
sure exactly the same volume, for example, because of
difficulties in identifying the basal (mitral valve) plane. It
is, therefore, very important to know the normal values
for each single technique with its specific equipment and
isotope, and the present study is helpful in establishing
this knowledge for the use of O-15–labeled CO PET
scans. At present, a major drawback is that each institu-
tion is using its own software, and therefore results
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cannot be directly compared between different sites.
Standardization of gated SPECT measurement provided the
base to its overwhelming success. Similarly, standardiza-
tion of gated PET data acquisition will advance acceptance
and importance of this precious technique.
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